Eduardo Santos, MD, FACP, FCCP

Edgardo S. Santos Castillero, MD, FACP, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer.

Eduardo Santos, MD, FACP, FCCP, highlights the most impactful and treatment-changing data updates for NSCLC in 2023, and provides perspective on how these finding may shape the future direction of care.

Eduardo Santos, MD, FACP, FCCP, discusses recent advances in dual immunotherapy approaches for NSCLC, highlighting data from the CheckMate 9LA study.

Eduardo Santos, MD, FACP, FCCP, delves into advancements in the treatment of squamous NSCLC, emphasizing crucial insights from the EMPOWER-Lung01 and EMPOWER-Lung03 subgroup analysis.

Eduardo Santos, MD, FACP, FCCP, highlights key takeaways from the latest EMPOWER-LUNG03 data and discusses the impact of these findings on the treatment setting.

Eduardo Santos, MD, FACP, FCCP, provides an overview of immunotherapy-based treatment strategies for advanced NSCLC, outlining key factors influencing treatment selection.

Dr. Eduardo Santos, MD, FACP, FCCP, examines immunotherapy-based treatment approaches for NSCLC in the adjuvant setting, highlighting updates from KEYNOTE-091.

Dr. Eduardo Santos, MD, FACP, FCCP, highlights advancements in neoadjuvant immunotherapy for NSCLC presented during key conferences in 2023, underscoring pivotal findings and the potential transformation of treatment approaches.

Dr. Eduardo Santos, MD, FACP, FCCP, provides and overview of immunotherapy-based treatment strategies for NSCLC in the neoadjuvant and perioperative setting.